NCT00788541

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 197 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Anecortave Acetate Sterile Suspension, 6 mg/mL	Administered as an injection into an anterior juxtascleral depot
DRUG	Anecortave Acetate Sterile Suspension, 3.75 mg/mL	Administered as an injection into an anterior juxtascleral depot
DRUG	Anecortave Acetate Sterile Suspension, 96 mg/mL	Administered as an injection into an anterior juxtascleral depot
DRUG	Anecortave Acetate Sterile Suspension, 60 mg/ML	Administered as an injection into an anterior juxtascleral depot
OTHER	Anecortave Acetate Vehicle	Administered as an injection into an anterior juxtascleral depot

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2008-11-11
• Last updated: 2012-11-30

Locations

1 site across 1 country: United States